Broad portfolio of imaging technology empowers clinicians to access the entire patient picture
Lexington, Mass., November 23, 2021 – FUJIFILM Healthcare Americas Corporation announced it will showcase its portfolio of medical imaging solutions at the 2021 Radiological Society of North America (RSNA) conference, booth #1911, held November 28 – December 2, 2021 at McCormick Place West in Chicago. This is the company’s first RSNA exhibition since integrating FUJIFILM Medical Systems U.S.A., Inc. and Hitachi Healthcare Americas on October 1, 2021. The new combined organization – now operating under name FUJIFILM Healthcare Americas Corporation – brings together the strengths of each company’s innovative product portfolios and talented employees to shape the future of diagnostic care.
For the first time at RSNA, attendees will get to experience Fujifilm’s latest advancements in digital radiography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound technologies, including:
“Image quality and patient-focused reliability has been at the very core of Fujifilm’s history for more than 85 years,” said Henry Izawa, president and CEO of FUJIFILM Healthcare Americas Corporation. “We’re looking forward to meeting with RSNA attendees in-person this year, and to demonstrate how Fujifilm is bringing the newest imaging technology to empower clinicians to expand what they see and understand as we help visualize the entire patient picture.”
At booth #1911, Fujifilm will also exhibit the following cutting-edge modality solutions, including:
To learn more about Fujifilm’s presence at RSNA 2021 and to schedule an on-site meeting, please visit: rsna.fujimed.com
FUJIFILM Healthcare Americas Corporation is a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery. The Synapse® Enterprise Imaging portfolio provides healthcare professionals with the imaging and data access needed to deliver a complete patient record. REiLI®, Fujifilm’s artificial intelligence initiative, combines Fujifilm’s rich image -processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. The In-Vitro Diagnostic portfolio provides the golden standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories across the country and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts. For more information please visit healthcaresolutions-us.fujifilm.com.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com